Genfit SA

Ipsen is making good progress in reducing its reliance on the acromegaly and neuroendocrine tumour blockbuster Somatuline, according to CEO David Loew who has heralded the launches of two rare disease

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a

The US Food and Drug Administration’s expectations for the timing of accelerated approval confirmatory trials came into clearer focus in 2024 with new policy documents and real-world examples. The age

The new drugs that hit the market in 2024 included medicines to address an array of high unmet medical need, but the US Food and Drug Administration approval of several drugs for liver disease put a s